» Articles » PMID: 3493441

Efficacy of Astatine-211-labeled Monoclonal Antibody in Treatment of Murine T-cell Lymphoma

Overview
Journal NCI Monogr
Specialty Oncology
Date 1987 Jan 1
PMID 3493441
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The short-lived isotope 211At (half-life, 7.2 hr), an alpha particle-emitting halogen, has been attached to a monoclonal antibody (anti-thy 1.1, IgG1, OX7) and used in mice in the treatment of a thy 1.1 T-cell lymphoma (A120). Forty-eight hours after receiving an iv injection of 10(3) or 10(5) A120 cells, mice were treated with phosphate-buffered saline, 211At-, antibody alone, or 211At conjugated to OX7. Treatment with the 211At-labeled OX7 conjugate increased the median survival time of mice and probably "cured" (survival at 200 days) 6 of the 15 mice given 10(5) cells and 21 of the 27 mice given 10(3) cells.

Citing Articles

Astatine Radiopharmaceuticals: Prospects and Problems.

Vaidyanathan G, Zalutsky M Curr Radiopharm. 2010; 1(3):177.

PMID: 20150978 PMC: 2818997. DOI: 10.2174/1874471010801030177.


Cancer radioimmunotherapy with alpha-emitting nuclides.

Couturier O, Supiot S, Degraef-Mougin M, Faivre-Chauvet A, Carlier T, Chatal J Eur J Nucl Med Mol Imaging. 2005; 32(5):601-14.

PMID: 15841373 DOI: 10.1007/s00259-005-1803-2.


Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells.

Aurlien E, Larsen R, Kvalheim G, Bruland O Br J Cancer. 2000; 83(10):1375-9.

PMID: 11044364 PMC: 2408791. DOI: 10.1054/bjoc.2000.1453.


Intratumour injection of immunoglobulins labelled with the alpha-particle emitter 211At: analyses of tumour retention, microdistribution and growth delay.

Larsen R, Bruland O Br J Cancer. 1998; 77(7):1115-22.

PMID: 9569048 PMC: 2150129. DOI: 10.1038/bjc.1998.185.


Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies in vitro with 211At-labelled monoclonal antibody.

Larsen R, Bruland O, Hoff P, Alstad J, Rofstad E Br J Cancer. 1994; 69(6):1000-5.

PMID: 8198960 PMC: 1969434. DOI: 10.1038/bjc.1994.196.